CDR-Life has formed a successful partnership with Boehringer Ingelheim, bringing together our antibody fragment expertise with Boehringer’s clinical development and marketing expertise.
We are open to partnering with companies, academic collaborators, and individuals who share our vision and can help bring CDR-Life’s innovations to patients.
Our team has a substantial track record in both forming and working in partnerships between pharma and biotech companies to bring new therapeutics to market for patients.
«Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics…»
Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research, Boehringer Ingelheim
Contact us for partnering opportunities.
konstantin.vonschulthess@cdr-life.com
BioEurope 2024, November 4 – 6, 2024, in Stockholm, Sweden
SITC, November 6 – 10, 2024, in Houston, Texas
Jefferies London 2024, November 19 – 21, 2024, in London, UK
ESMO Immuno Oncology, December 11 – 13, 2024, in Geneva, Switzerland
JPM 2025, January 13 – 16, 2025, in San Francisco, California